Vaginal DHEA (Prasterone)
Vaginal DHEA (prasterone / Intrarosa) is an FDA-approved intravaginal steroid for moderate-to-severe dyspareunia due to menopause. Its defining pharmacologic feature — intracrine conversion to both androgens and estrogens exclusively within vaginal cells — distinguishes it from vaginal estrogen by providing dual androgenic and estrogenic local effects without clinically significant systemic hormone elevation.[1][2][3] The consequence is a broader sexual-function benefit — improvement across all six FSFI domains including desire and arousal, which vaginal estrogen alone does not reliably address.[4]
For related agents, see Vaginal and topical estrogen, Ospemifene, and Preoperative hormonal priming. For the clinical framework, see GSM.
Mechanism — the science of intracrinology
Prasterone (synthetic DHEA) exploits intracrinology — inactive precursor hormones are converted into active sex steroids within target cells, act locally, and are then inactivated before release into circulation.[2]
Enzymatic cascade within vaginal tissue:[5][2]
- DHEA → androstenedione (3β-HSD1/HSD2)
- Androstenedione → testosterone (17β-HSD3/HSD5)
- Testosterone → DHT (5α-reductase isoforms)
- Androstenedione → estrone → estradiol (aromatase + 17β-HSD)
- Active steroids → glucuronide/sulfate conjugates (UGT + SULT) → released as inactive metabolites
Cellai 2021 confirmed the human vagina as an androgen-target organ — DHEA supplementation of human vaginal smooth-muscle cells increased androstenedione, testosterone, and DHT secretion and activated AR-dependent gene expression.[5]
Clinical consequence: after menopause, ovarian estrogen production ceases, and DHEA (the remaining endogenous androgen-estrogen precursor) declines progressively from age ~30. Delivering DHEA directly to the vagina restores both the estrogenic effects (epithelial maturation, lubrication, pH normalization) and the androgenic effects (muscularis support, improved blood flow, enhanced sexual function) of a premenopausal hormonal milieu — advantages that vaginal estrogen alone cannot deliver.[2][6]
FDA-approved indication and dosing
| Element | Details |
|---|---|
| Brand | Intrarosa[3] |
| US indication | Moderate-to-severe dyspareunia — a symptom of vulvar and vaginal atrophy due to menopause |
| EU indication | Treatment of VVA in postmenopausal women with moderate-to-severe symptoms (broader than US) |
| Dose | One vaginal insert (6.5 mg prasterone) once daily at bedtime via the provided applicator |
| Loading / taper | None |
| Progestogen | Not required for endometrial protection[7] |
| Absolute contraindication | Undiagnosed abnormal genital bleeding |
| Label warning | Estrogen is a metabolite of prasterone; exogenous estrogen is contraindicated in women with known/suspected breast cancer; Intrarosa has not been studied in breast cancer survivors |
| Pediatric | Safety not established |
| Hepatic / renal impairment | PK not studied; ~19% of clinical-trial participants were ≥65 y |
Pivotal clinical trials
Approval rested on two Phase III placebo-controlled RCTs (ERC-231, ERC-238) plus the 52-week open-label safety trial ERC-230.[3][8]
Coprimary endpoints — all four met in both trials[1]
| Endpoint | Effect over placebo | p |
|---|---|---|
| Parabasal cells (%) | ↓ 27.7% | <0.0001 |
| Superficial cells (%) | ↑ 8.44% | <0.0001 |
| Vaginal pH | ↓ 0.66 units | <0.0001 |
| Dyspareunia severity | ↓ 0.36 units over placebo (−1.42 from baseline) | 0.0002 |
| Vaginal dryness (key secondary) | ↓ 0.27 units over placebo (−1.44 from baseline) | 0.004 |
On gynecologic evaluation, vaginal secretions, epithelial integrity, surface thickness, and color all improved 86–121% over the placebo effect (p < 0.0001).[1]
2026 meta-analysis — Lemos
Systematic review and meta-analysis of 6 RCTs (5 unique; n = 1,611):[9]
- Vaginal dryness: MD −0.23 (95% CI −0.35 to −0.11) vs placebo
- Dyspareunia: MD −0.40 (95% CI −0.66 to −0.15) vs placebo
- No major safety concerns; AEs mild and infrequent
- Low-to-moderate heterogeneity
Sexual function — all six FSFI domains improve
The headline differentiator from vaginal estrogen. Labrie 2015 Phase III FSFI analysis (n = 482) — all six FSFI domains improved significantly over placebo at 12 weeks:[4]
| FSFI domain | Improvement vs placebo | p |
|---|---|---|
| Desire | +49.0% | 0.0105 |
| Arousal | +56.8% | 0.0022 |
| Lubrication | +36.1% | 0.0005 |
| Orgasm | +33.0% | 0.047 |
| Satisfaction | +48.3% | 0.0012 |
| Pain | +39.2% | 0.001 |
| Total FSFI | +41.3% | 0.0006 |
An earlier dose-finding Phase III (Labrie 2009, n = 216) showed dose-dependent improvements in arousal/sensation (+68%, p = 0.006), arousal/lubrication (+39%, p = 0.0014), orgasm (+75%, p = 0.047), and dryness during intercourse (−57%, p = 0.0001) with the 1.0% DHEA dose.[6]
The desire and arousal signal — not reliably delivered by vaginal estrogen — is attributable to local androgenic action of DHEA metabolites (testosterone, DHT) on vaginal smooth muscle, nerve endings, and blood flow.[4][6]
Systemic absorption — the core safety argument
Integrated LC-MS/MS serum steroid analysis (n = 723 DHEA + n = 266 placebo) after 12 weeks of 6.5 mg daily:[10][11]
| Steroid | 12-wk level on DHEA | Normal postmenopausal value | Interpretation |
|---|---|---|---|
| Estradiol (E2) | 3.26–3.36 pg/mL | 4.17 pg/mL | 19–22% BELOW normal postmenopausal |
| Estrone sulfate (E1-S) | 209–219 pg/mL | 220 pg/mL | Superimposable |
| Testosterone | Slightly ↑ | Within postmenopausal range | Lowest half of the range |
| DHEA-S | ↑ (dose-dependent) | Within postmenopausal range | — |
| ADT-G (androgen metabolite) | Within range | Normal postmenopausal | No excess androgenic activity |
The serum E2 below average postmenopausal is the critical datum — vaginal DHEA does not meaningfully raise systemic estrogen.[10][11]
In cancer survivors — NCCTG N10C1 (Alliance)
Barton 2018 (n = 345 blood samples in women with breast or gynecologic cancer history) — 3.25 mg vs 6.5 mg DHEA vs plain moisturizer:[12]
- DHEA-S and testosterone rose dose-dependently but stayed in the lowest half or quartile of the postmenopausal range
- Estradiol increased with 6.5 mg but not with 3.25 mg (p = 0.05)
- Critically, estrogen concentrations in women on aromatase inhibitors were NOT changed — the AI blocks systemic DHEA-to-estrogen conversion
- Biomarkers of bone formation unchanged in all arms
- Vaginal maturation improved: 100% (3.25 mg), 86% (6.5 mg), 64% (moisturizer)
This is the pharmacologic basis for considering vaginal DHEA in AI users despite the general warning about estrogen metabolites.
Comparison with vaginal estrogen
Archer 2017 indirect cross-trial comparison of prasterone 6.5 mg vs CEE 0.3 mg vs estradiol 10 µg:[13]
| Outcome | Prasterone 6.5 mg | CEE 0.3 mg | Estradiol 10 µg |
|---|---|---|---|
| Dyspareunia — total Δ from baseline | 1.27–1.63 | 1.4 | 1.23 |
| Dyspareunia — Δ over placebo | 0.35–1.21 | 0.7–1.0 | 0.33 |
| Dryness — total Δ from baseline | 1.44–1.58 | 1.1 | 1.23 |
| Dryness — Δ over placebo | 0.30–0.43 | 0.40 | 0.33 |
Authors: prasterone "appears to be at least as efficacious as 0.3 mg CEE or 10 µg estradiol" for VVA symptoms.[13] A 2023 JAMA review estimated symptom-improvement ranges of 60–80% (vaginal estrogen) vs 40–80% (prasterone) vs 30–50% (oral ospemifene).[14]
Advantages of prasterone vs vaginal estrogen
- All six FSFI domains improve including desire and arousal[4]
- Androgenic effects on muscularis and lamina propria (deeper tissue layers)[6]
- Serum E2 below normal postmenopausal values[10]
- May be safer in AI users — systemic E2 unchanged in AI users in NCCTG[12]
Disadvantages vs vaginal estrogen
- Daily dosing (vs 2×/wk inserts or 90-day ring)
- Vaginal discharge from melting vehicle (~6–14%)[1][3]
- More expensive; no generic
- No UTI-prevention evidence — vaginal estrogen is the AUA-endorsed rUTI agent (RR 0.42)[15]
- No head-to-head RCT vs vaginal estrogen[15]
See Vaginal and topical estrogen for the rUTI data.
Adverse effects and safety
Short-term (pooled 4 RCTs, n = 665 DHEA + n = 464 placebo)[3]
Only AE with ≥2% incidence and greater than placebo: vaginal discharge 5.71% (DHEA) vs 3.66% (placebo) — melting of the suppository vehicle at body temperature, not pathologic.
Long-term (52-wk open-label ERC-230, n = 521)[8][3]
- Vaginal discharge: 14.2% (74/521)
- Abnormal Pap: 2.1% (11/521) — 10 ASCUS, 1 LSIL
- No endometrial hyperplasia or carcinoma
- No clinically significant serum-steroid changes beyond normal postmenopausal ranges
- No drug-related serious AEs
Androgenic side effects
Cochrane review of DHEA (all routes) found an association with androgenic AEs, mainly acne (OR 3.77; 95% CI 1.36–10.4; p = 0.01), but this was primarily driven by oral/systemic DHEA — not the intravaginal 6.5 mg formulation.[16]
Endometrial safety
No progestogen required; no hyperplasia in 52-wk data. Maximum RCT endometrial safety data is 52 weeks — long-term safety beyond this window is not established. Patients must be counseled to report any vaginal bleeding promptly.[14]
Use in breast cancer survivors
The most nuanced clinical question. The FDA label carries a warning; guideline positions are cautious but allow use.
| Source | Position |
|---|---|
| FDA label | Estrogen is a metabolite; use of exogenous estrogen is contraindicated in women with known/suspected breast cancer; Intrarosa has not been studied in this population[3] |
| ACOG 2021 clinical consensus | "If vaginal estrogen is not an option, vaginal DHEA or testosterone may help with dyspareunia and improve vaginal tissue health" — second-line after vaginal estrogen[17] |
| NCCN Survivorship 2026 | Listed among "other topical hormones" for vaginal dryness; "limited data regarding the use of androgen therapy in survivors of hormonally mediated cancers"; "more information needed … particularly for breast cancer survivors on AIs"[18] |
| NCCN Breast Cancer Risk Reduction 2026 | "Consider avoiding bioidentical hormones or DHEA" in women on risk-reducing agents[19] |
VIBRA pilot — Mension 2022
10 breast cancer survivors on AIs, 6 months of vaginal prasterone:[20]
- Mean serum E2 3.4 → 4.3 pg/mL (p = 0.91 — not significant)
- Dyspareunia VAS 8.5 → 0.4 (p = 0.018)
- VHI 9.75 → 15.8 (p = 0.028)
- FSFI 11.2 → 20.6 (p = 0.028)
- Vaginal pH 8.1 → 6.5 (p = 0.033)
Pharmacologic rationale in AI users
Because AIs block aromatase — the enzyme converting DHEA-derived androgens to estrogens — DHEA-derived androgens cannot be systemically converted to estrogens in AI users. NCCTG confirmed estrogen concentrations unchanged in AI users receiving vaginal DHEA.[12] Local intravaginal aromatase activity may still convert some DHEA to estrogen within the vagina — the intended therapeutic effect and the residual theoretical concern.
Bottom line
Vaginal DHEA is a reasonable option in breast cancer survivors, particularly for AI users where systemic E2 conversion is blocked. Data are limited, the FDA label carries a warning, and shared decision-making with oncology is essential.[17][20][21]
Practical prescribing
| Parameter | Recommendation |
|---|---|
| Ideal candidate | Postmenopausal woman with moderate-to-severe dyspareunia ± dryness who wants sexual-function improvement beyond what estrogen alone provides, or who prefers a non-estrogen option[1] |
| Dose | 6.5 mg vaginal insert nightly at bedtime[3] |
| Onset | Significant improvement by 6 weeks; full effect by 12 weeks[1] |
| Duration | Indefinite — GSM is chronic; symptoms recur on discontinuation[3] |
| Progestogen | Not required[3] |
| Monitoring | No routine serum monitoring; evaluate any postmenopausal bleeding[14] |
| Patient counseling | ~6–14% vaginal discharge from melting vehicle — not a sign of infection; panty liner if bothersome[1][3] |
| Breast cancer survivors | Second-line after vaginal estrogen (ACOG); shared decision with oncology; favorable pharmacology in AI users[17][20] |
| Cost | Brand-name only (~$200–300/month without insurance); no generic |
| Storage | Refrigerate 2–8 °C; room temperature 20–25 °C for up to 7 days[3] |
Comparative summary — DHEA vs vaginal estrogen vs ospemifene
| Feature | Vaginal DHEA (prasterone) | Vaginal estrogen | Ospemifene (oral SERM) |
|---|---|---|---|
| FDA indication | Dyspareunia (US); VVA (EU) | GSM symptoms | Dyspareunia + vaginal dryness |
| Mechanism | Intracrine → androgens + estrogens | Direct estrogenic | Oral SERM (vaginal agonist) |
| Dosing frequency | Daily | 2×/wk or 90-day ring | Daily oral |
| FSFI all 6 domains | Yes (including desire and arousal)[4] | Primarily pain / lubrication | Dyspareunia |
| UTI prevention | Not studied | Strong evidence (RR 0.42)[15] | Not studied |
| Serum E2 | Below normal postmenopausal | Very low (formulation-dependent) | Systemic (oral) |
| Progestogen needed | No | No (low dose) | No |
| Breast cancer survivors | Second-line; favorable pharmacology in AI users | First-line hormonal (after non-hormonal); shared decision-making | Approved in some jurisdictions |
| Main AE | Vaginal discharge 6–14% | Discharge / irritation | Hot flashes ~10% |
| Generic? | No | Yes (most) | No |
| Symptom improvement | 40–80%[14] | 60–80% | 30–50% |
Evidence Summary
| Domain | Evidence level | Key source |
|---|---|---|
| Dyspareunia efficacy | Level 1 (Phase III RCTs + meta-analysis) | Labrie 2018 pivotal[1]; Lemos 2026 meta[9] |
| All-FSFI-domain sexual function | Level 1 (Phase III FSFI analysis) | Labrie 2015[4]; Labrie 2009[6] |
| Systemic absorption / safety | Level 1 (pharmacology studies) | Ke 2015[10]; Martel 2016[11] |
| Long-term safety | Level 2 (52-wk open-label) | ERC-230[8] |
| Breast cancer survivors — pharmacology | Level 2 | NCCTG Barton 2018[12]; VIBRA 2022[20] |
| Indirect comparison vs vaginal estrogen | Level 3 | Archer 2017[13] |
| UTI prevention | Not studied | — |
Clinical Positioning
- Vaginal DHEA 6.5 mg nightly is FDA-approved for moderate-to-severe dyspareunia due to menopause and is supported by two Phase III placebo-controlled RCTs meeting all four coprimary endpoints.[1][3]
- The sexual-function benefit is broader than vaginal estrogen — all six FSFI domains improve, including desire and arousal, attributable to the androgenic-metabolite action on vaginal smooth muscle and blood flow.[4]
- Systemic hormone safety is excellent. Serum E2 stays below normal postmenopausal values and testosterone stays in the lowest half of the range at the 6.5 mg dose.[10][11]
- No progestogen is required and no endometrial hyperplasia was seen at 52 weeks; long-term (>1 y) endometrial data are absent — evaluate any postmenopausal bleeding.[3][8][14]
- Prasterone does not prevent UTIs. Vaginal estrogen remains the AUA-endorsed agent for rUTI prevention (RR 0.42). Do not substitute DHEA for UTI-driven indications.[15]
- In breast cancer survivors, DHEA is second-line after vaginal estrogen per ACOG and reasonable in AI users given the pharmacologic block on systemic estrogen conversion. The VIBRA pilot supports short-term safety and symptomatic benefit on AIs.[17][20]
- Counsel about vaginal discharge from melting vehicle — 6% short-term, 14% long-term; not infectious; panty liner usually sufficient.[1][3]
- Cost and daily dosing are the practical downsides — no generic, ~$200–300/month; nightly application compared to 2×/wk or 90-day estrogen-ring alternatives.
- Onset is gradual — 6-week partial benefit, 12-week full effect — match expectations accordingly.[1]
- Refrigerate before use, but the product tolerates room temperature for up to 7 days for travel.[3]
See Also
References
1. Labrie F, Archer DF, Koltun W, et al. "Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause." Menopause. 2018;25(11):1339–1353. doi:10.1097/GME.0000000000001238
2. Labrie F, Bélanger A, Pelletier G, et al. "Science of intracrinology in postmenopausal women." Menopause. 2017;24(6):702–712. doi:10.1097/GME.0000000000000808
3. US Food and Drug Administration. Intrarosa (prasterone) — prescribing information. Updated 2025-01-01.
4. Labrie F, Derogatis L, Archer DF, et al. "Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy." J Sex Med. 2015;12(12):2401–2412. doi:10.1111/jsm.13045
5. Cellai I, Di Stasi V, Comeglio P, et al. "Insight on the intracrinology of menopause: androgen production within the human vagina." Endocrinology. 2021;162(2):bqaa219. doi:10.1210/endocr/bqaa219
6. Labrie F, Archer D, Bouchard C, et al. "Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women." Menopause. 2009;16(5):923–931. doi:10.1097/gme.0b013e31819e85c6
7. Labrie F, Luu-The V, Labrie C, et al. "Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone." Endocr Rev. 2003;24(2):152–182. doi:10.1210/er.2001-0031
8. Heo YA. "Prasterone: a review in vulvovaginal atrophy." Drugs Aging. 2019;36(8):781–788. doi:10.1007/s40266-019-00693-6
9. Lemos MJ, Queiroz LF, Diniz AF, et al. "Intravaginal dehydroepiandrosterone for the treatment of vulvovaginal atrophy: a systematic review and meta-analysis." Menopause. 2026. doi:10.1097/GME.0000000000002736
10. Ke Y, Labrie F, Gonthier R, et al. "Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration." J Steroid Biochem Mol Biol. 2015;154:186–196. doi:10.1016/j.jsbmb.2015.08.016
11. Martel C, Labrie F, Archer DF, et al. "Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks." J Steroid Biochem Mol Biol. 2016;159:142–153. doi:10.1016/j.jsbmb.2016.03.016
12. Barton DL, Shuster LT, Dockter T, et al. "Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)." Support Care Cancer. 2018;26(4):1335–1343. doi:10.1007/s00520-017-3960-9
13. Archer DF, Labrie F, Montesino M, Martel C. "Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 µg estradiol on symptoms of vulvovaginal atrophy." J Steroid Biochem Mol Biol. 2017;174:1–8. doi:10.1016/j.jsbmb.2017.03.014
14. Crandall CJ, Mehta JM, Manson JE. "Management of menopausal symptoms: a review." JAMA. 2023;329(5):405–420. doi:10.1001/jama.2022.24140
15. Danan ER, Sowerby C, Ullman KE, et al. "Hormonal treatments and vaginal moisturizers for genitourinary syndrome of menopause: a systematic review." Ann Intern Med. 2024;177(10):1400–1414. doi:10.7326/ANNALS-24-00610
16. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. "Dehydroepiandrosterone for women in the peri- or postmenopausal phase." Cochrane Database Syst Rev. 2015;1:CD011066. doi:10.1002/14651858.CD011066.pub2
17. American College of Obstetricians and Gynecologists. "Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer: clinical consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601
18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: survivorship. Updated 2026-04-08.
19. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction. Updated 2025-08-29.
20. Mension E, Alonso I, Cebrecos I, et al. "Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study." Climacteric. 2022;25(5):476–482. doi:10.1080/13697137.2022.2050208
21. Gompel A, Simcock R. "Menopausal hormone treatment and breast cancer." Lancet Diabetes Endocrinol. 2026. doi:10.1016/S2213-8587(25)00394-8